PRN®Pharmacal Names Orach Product Manager Continuation of Team Growth in Pensacola

(Pensacola, Fla. " March 7, 2013) " Pegasus Laboratories, makers of PRN® Pharmacal branded products, has named Christy Orach as PRN Pharmacal Product Manager. Orach’s hiring is a continuation of establishing a more robust marketing and sales team in Pensacola following animal health industry veteran Jeff Santosuosso being named Vice President-General Manager.

Christy Orach
PRN Pharmacal
Product Manager

As PRN Pharmacal Product Manager, Orach is responsible for championing existing and new products through their life cycle. She recently completed a successful launch of Collasate® Silver gel, the first wound healing product for pets to combine collagen and silver oxide.

“Christy understands the complexities of the veterinary business and the importance of providing information the veterinary healthcare team can easily use in a clinic setting. She’s detail-oriented and a team player which is important as we continue to grow,” said Jeff Santosuosso, Vice President-General Manager said.

Orach has nine years of extensive brand experience across several vertical markets. Her animal health experience as an agency brand manager includes overseeing eight Merial branded products including facilitating a new product launch and corresponding marketing campaign targeting equine veterinarians, a product trial program which included the creation of various marketing touch points, marketing communications plans and launching Merial’s first-ever social media spokesperson contest.Orach earned her Bachelor of Science degree in journalism from the University of Kansas in 2003.

Pegasus Laboratories manufactures products which are distributed and marketed to the veterinary profession under the name PRN Pharmacal. Brand names include PROIN® for canine urinary incontinence and the newly introduced Collasate Silver® gel to its line of wound care treatment products among others. To learn more about PRN Pharmacal products, visit or call 1-800-874-9764.


Comments are closed.